$1.99
+0.09 (+4.74%)
Open$1.90
Previous Close$1.90
Day High$2.03
Day Low$1.85
52W High$35.81
52W Low$29.00
Volume—
Avg Volume244.3K
Market Cap19.43M
P/E Ratio26.00
EPS$1.29
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,939.2% upside
Current
$1.99
$1.99
Target
$40.58
$40.58
$25.27
$40.58 avg
$56.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.34M | 7.69M | 6.20M |
| Net Income | 836.8K | 704.4K | 655.3K |
| Profit Margin | 11.4% | 9.2% | 10.6% |
| EBITDA | 1.33M | 1.40M | 1.15M |
| Free Cash Flow | 524.0K | 541.1K | 340.9K |
| Rev Growth | +8.2% | -3.9% | -5.2% |
| Debt/Equity | 0.19 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |